natgillin/translations-raw huggingface dataset:
In a study in which bortezomib retreatment was administered in 130 patients with relapsed multiple myeloma, who previously had at least partial response on a bortezomib-containing regimen, the most common all-grade adverse events occurring in at least 25% of patients were thrombocytopenia (55%), neuropathy (40%), anaemia (37%), diarrhoea (35%), and constipation (28%).
Najpogostejši neželeni učinki (vseh stopenj), ki so se pojavili pri najmanj 25% bolnikov so bili trombocitopenija (55%), nevropatija (40%), anemija (37%), diareja (35%) in zaprtje (28%).
1.1 Preparation of the 3.5 mg vial: carefully add 1.4 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib Accord powder by using a syringe of the appropriate size without removing the vial stopper.
Priprava 3,5 mg viale: previdno dodajte 1,4 ml sterilne 9 mg/ml (0,9%) raztopine natrijevega klorida za injiciranje v vialo s praškom zdravila Bortezomib Accord.
Posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)
Priporočeno odmerjanje pri bolnikih, pri katerih diseminirani plazmocitom še ni bil zdravljen in so primerni za presaditev krvotvornih matičnih celic (uvajalno zdravljenje)
*CR+nCR
*RR (po presaditvi) CR+nCR
Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache*
omotica*, disgevzija*, letargija, glavobol*
Antiviral prophylaxis was administered to 26% of the patients in the Bz+M+P arm.
V Bz+M+P kraku študije je protivirusna zdravila prejelo 26% bolnikov.
However, the chemical and physical in-use stability has been demonstrated for 8 hours at 20°C-25°C stored in the original vial and/or a syringe.
Zdravilo je kemično in fizikalno stabilno 8 ur pri temperaturi do 25°C, če ga pred uporabo shranjujemo v originalni viali in/ali injekcijski brizgi.
Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma
Klinična učinkovitost zdravila pri bolnikih s predhodno nezdravljenim limfomom plaščnih celic
If you are given Bortezomib Accord for multiple myeloma or mantle cell lymphoma, tell your doctor straight away if you notice any of the following symptoms: - muscle cramping, muscle weakness - confusion, visual loss or disturbances, blindness, seizures, headaches - shortness of breath, swelling of your feet or changes in your heart beat, high blood pressure,
- mišični krči, mišična šibkost - zmedenost, izguba ali motnje vida, slepota, epileptični napadi, glavoboli - težko dihanje, otekanje nog ali spremembe srčnega utripa, visok krvni tlak, utrujenost,
The mean distribution volume (Vd) of bortezomib ranged from 1,659 l to 3,294 l following single- or repeated-dose intravenous administration of 1.0 mg/m2 or 1.3 mg/m2 to patients with multiple myeloma.
Biotransformacija Po enkratnem ali večkratnem intravenskem dajanju odmerkov 1,0 mg/m2 ali 1,3 mg/m2 bolnikom z diseminiranim plazmocitomom je bil povprečni volumen porazdelitve (Vd) 1,659 l do 3294 l. To nakazuje, da se bortezomib v veliki meri porazdeljuje v periferna tkiva.
(e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding from the liver) - red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness - white blood cells may make you more prone to infections or flu-like symptoms.
- krvnih ploščic, zaradi česar ste lahko bolj dovzetni za podplutbe ali krvavitve brez očitnih poškodb (npr.: krvavitve v črevesju, želodcu, ustih in dlesnih ali krvavitve v možganih ali jetrih).
d p-value from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors; analysis by line of therapy excludes stratification for therapeutic history * CR+PR+MR **CR=CR, (IF-); nCR=CR (IF+)
* CR+PR+MR; **CR=CR, (IF-); nCR=CR (IF+)
Twice weekly Bortezomib Accord (cycles 1-4) Week Bz (1.3 mg/m
Odmerjanje zdravila Bortezomib Accord dvakrat na teden (krogi 1-4)
PRES is a rare, often reversible, rapidly evolving neurological condition, which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances.
Pri bolnikih, ki so prejemali bortezomib, so poročali o PRES. PRES je redka, pogosto reverzibilna nevrološka motnja, ki se razvije hitro in se lahko kaže z epileptičnimi napadi, hipertenzijo, glavoboli,
Limited information on bortezomib retreatment in relapsed multiple myeloma is available.
Na voljo so le omejeni podatki o ponovnem zdravljenju z bortezomibom pri bolnikih s ponovitvijo diseminiranega plazmocitoma.
One hundred and thirty patients (≥ 18 years of age) with multiple myeloma who previously had at least partial response on a bortezomib-containing regimen were retreated upon progression.
Bolnike, ki so predhodno imeli vsaj delni odgovor na režim zdravljenja z bortezomibom so ponovno zdravili po napredovanju bolezni.
• Hormone abnormality which may affect salt and water absorption
• poslabšanje sluha, gluhost ali zvonjenje v ušesih, nelagodje v ušesu • hormonske motnje, ki lahko vplivajo na absorpcijo soli in vode
Bortezomib Accord is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 28-day treatment cycle.
Priporočeni odmerek je 1,3 mg/m2 telesne površine, dvakrat na teden dva tedna, na dan 1, 4, 8 in 11 v 28 dnevnem krogu zdravljenja.
Gastrointestinal toxicity, including nausea, diarrhoea, vomiting and constipation are very common with bortezomib treatment.
Med zdravljenjem z bortezomibom se zelo pogosto pojavijo toksični učinki na prebavila, kot so slabost, driska, bruhanje in zaprtje.
• Hernia
OVOJNINAH
This medicine is for intravenous or subcutaneous use.
To zdravilo se daje samo intravensko.
Severity of neuropathy
Stopnja nevropatije
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
CR=popolni odgovor; CRu=nepotrjen popšolni odgovor; PR=delni odgovor; CI=interval zaupanja, HR=razmerje tveganja; OR=razmerje verjetnosti; ITT=populacija, ki so jo nameravali zdraviti
• If local injection site reactions occur following Bortezomib Accord injection subcutaneously, either a less concentrated Bortezomib Accord solution (1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
• Če se po subkutanem injiciranju zdravila Bortezomib Accord na mestu injiciranja pojavijo lokalne reakcije, se priporoča, da subkutano injicirate manj koncentrirano raztopino zdravila
In the event of an overdose, the patient's vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).
(npr.: tekočine, učinkovine, ki zvišujejo krvni tlak, in/ali inotropne učinkovine) in telesne temperature
Oedema (inc peripheral), Chills, Pain*, Malaise*
Pogosti dispneja*, kašelj*, kolcanje
Bortezomib Accord powder has to be dissolved before administration.
Bortezomib Accord mora preteči najmanj 72 ur.
Very Common Nausea and vomiting symptoms*, Diarrhoea*, Constipation Common
Zelo pogosti bolezni las* Pogosti srbenje*, dermatitis*, izpuščaj*
A Phase II, single arm activity, safety, and pharmacokinetic trial conducted by the Children's Oncology Group assessed the activity of the addition of bortezomib to multi agent re induction
V farmakokinetični študiji varnosti in učinkovitosti faze II, z enim krakom, ki jo je izvedla Skupina za otroško onkologijo (COG - Children's Oncology Group), so ocenili delovanje bortezomiba, ki so ga dodali k ponovno uvedeni indukcijski kemoterapiji z več zdravili pri pediatričnih in mladih odraslih bolnikih z limfatičnimi malignomi (s pre-B-celično akutno limfoblastno levkemijo [ALL], T-celično ALL in T-celičnim limfoblastnim limfomom [LL]).
Table 4: Posology for Bortezomib Accord combination therapy for patients with previously untreated multiple myeloma eligible for haematopoietic stem cell transplantation
Preglednica 4: Priporočeno odmerjanje zdravila Bortezomib Accord pri bolnikih, s predhodno nezdravljenim diseminiranim plazmocitomom, pri katerih je presaditev hematopoetskih matičnih celic primerna.
In study LYM-3002, colony stimulating factor support was given to 78% of patients in the BzR-CAP arm and 61% of patients in the R-CHOP arm.
78% bolnikov v skupini BzR-CAP in 61% bolnikov v skupini R-CHOP.
Median duration Days (months) Time to response CR+PR (days)
CR + PR (dnevi)
• If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle
• Pri bolnikih z infiltracijo kostnega mozga ali sekvestracijo vranice mora biti število trombocitov
SC or IV
S. k. ali i.v.
• In cycles 5 to 9, Bortezomib Accord is administered once weekly on days 1, 8, 22 and 29.
1., 4., 8., 11., 22., 25., 29. in 32. dan. - V krogih 5 do 9 pa enkrat na teden, 1., 8., 22. in 29. dan.
• If platelet counts < 25,000 cells/μL.
< 25.000 celic/μl ali ANC < 750 celic/μl.
Bortezomib Accord is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21 day treatment cycle.
Priporočeni odmerek je 1,3 mg/m2 telesne površine, dvakrat na teden dva tedna, na 1., 4., 8. in 11. dan v 21 dnevnem krogu zdravljenja.
Muscle twitching, Joint swelling, Arthritis*, Joint stiffness, Myopathies*,Sensation of heaviness
Občasni trzanje mišic, otekanje sklepov, artritis*, okorelost sklepov,
Day rest period rest period
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose, schedule or route of administration to subcutaneous (see section 4.2).
Pri bolnikih, pri katerih se periferna nevropatija pojavi prvič ali se obstoječa periferna nevropatija poslabša, je treba napraviti nevrološko oceno in po potrebi prilagoditi odmerek ali shemo odmerjanja
Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention Uncommon Tumour lysis syndrome
hipernatriemija*, nenormalne koncentracije sečne kisline*, sladkorna bolezen*, zastajanje tekočine
Rhabdomyolysis, Temporomandibular joint syndrome, Fistula, Joint effusion, Pain in jaw, Bone disorder, Musculoskeletal and connective tissue infections and inflammations*, Synovial cyst
izliv v sklep, bolečina v čeljusti, bolezni kosti, okužbe in vnetja mišično-skeletnega sistema, vezivnega tkiva*, sinovialna cista
tiredness, fainting - coughing and breathing difficulties or tightness in the chest.
oteženo ali preneha, sopenje • kolcanje, motnje govora
Hazard ratiob (95% CI) p-valuec a Kaplan-Meier estimate.
Ocena po metodi Kaplan-Meier.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi manitol (E 421)
• Multi-organ failure
• izguba telesne mase
≥ 25,000 cells/μL, Bortezomib Accord may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2).
• Če toksičnost mine oz. ima bolnik ANC ≥ 750 celic/μl in število trombocitov ≥ 25.000 celic/μl, lahko ponovno uvedete zdravilo Bortezomib Accord v odmerku, ki je eno stopnjo nižji od prejšnjega(z 1,3 mg/m2 na 1 mg/m2 ali z 1 mg/m2 na
Very Common Thrombocytopenia*, Neutropenia*, Anaemia* Common
Zelo pogosti trombocitopenija*, nevtropenija*, anemija* Pogosti levkopenija*, limfopenija*
Atrial flutter, Myocardial infarction*, Atrioventricular block*, Cardiovascular disorder (inc cardiogenic shock), Torsade de pointes, Angina unstable, Cardiac valve disorders*, Coronary artery insufficiency, Sinus arrest
srčno-žilne bolezni (vključno s kardiogenim šokom), Torsade de pointes, nestabilna angina pektoris, bolezni srčnih zaklopk*,
• If toxicity resolves i.e. patient has an
• Če je na dan odmerjanja zdravila
Day 22
27 mesecev
Leukopenia*, Anaemia*, Lymphopenia* Uncommon Pancytopenia*
levkocitoza*, limfadenopatija, hemolitična anemija#
breathing that becomes shallow, difficult or stops, wheezing
oteženo ali preneha, sopenje.
Cardiac disorders Uncommon
Organski sistem Pogostnost Neželeni učinek
Nine treatment cycles of this combination therapy are administered.
Zdravljenje z zdravilom Bortezomib Accord traja devet krogov.
- platelets, which may make you be more prone to bruising, or to bleeding without obvious injury
- belih krvnih celic in tako bolj dovzetni za okužbe ali gripi podobne simptome.
• Alteration of liver function
• zvišana telesna temperatura
Gastrointestinal haemorrhage (inc mucosal)*, Dyspepsia, Stomatitis*, Abdominal distension, Oropharyngeal pain*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*, Flatulence
sindrom kašlja zgornjih dihalnih poti (UACS - Upper-airway cough syndrome) Bolezni prebavil Zelo pogosti simptomi navzee in bruhanja*, driska*, zaprtje Pogosti krvavitev v prebavilih (vključno s sluznico)*, dispepsija, stomatitis*, napetost v trebuhu, bolečina v žrelu in grlu*, bolečina v trebuhu (vključno z bolečino v prebavilih in vranici)*, bolezni ust*, flatulenca
• Genital pain, problem having an erection
• vnetje trebušne slinavke, zapora žolčevoda • bolečina v spolovilih, motnje pri doseganju erekcije
If local injection site reactions occur following Bortezomib Accord subcutaneous injection, either a less concentrated Bortezomib Accord solution (Bortezomib Accord 3.5 mg to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
Bortezomib Accord (1 mg/ml namesto 2,5 mg/ml) ali pa preidete na intravensko dajanje zdravila.
Very Common Nausea and vomiting symptoms*, Diarrhoea*, Stomatitis*, Constipation
Zelo pogosti zvišana telesna temperatura*, izčrpanost, astenija
Dysacusis (inc tinnitus)* Uncommon Vertigo*, Hearing impaired (up to and inc deafness) Cardiac disorders Common
Občasni vertigo*, okvara sluha (vse do in vključno z gluhostjo)
T 200 mg a
T 200 mga na dan na dan na dan na dan
The exact mechanism of this interaction is not clear.
Natančen mehanizem te interakcije ni jasen.
This may happen:
To se lahko zgodi, če:
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 29 June 2009
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 29. junij 2009
Date of latest renewal: 19 June 2014
Datum zadnjega podaljšanja: 19. junij 2014
Talk to your doctor if any of the above applies to you.
Obvestite svojega zdravnika, če kar koli od naštetega velja za vas.
Your diabetes may get worse.
Sladkorna bolezen se vam lahko poslabša.
Hungary (Headquarters: 4042 Debrecen, Pallagi út 13)
Madžarska (Headquarters: 4042 Debrecen, Pallagi út 13)
Repaglinide has no direct influence on the ability to drive and use machines but may cause hypoglycaemia.
Zdravilo Repaglinid nima neposrednega vpliva na sposobnost vožnje in upravljanja s stroji, vendar pa lahko povzroči hipoglikemijo.
The amount of Repaglinide Teva, food or exercise may need to be adjusted.
Morda bo treba prilagoditi količino zdravila Repaglinid Teva, hrano ali telesno dejavnost.
Repaglinide has been given with weekly escalating doses from 4 - 20 mg four times daily in a 6 week period.
Repaglinid so dajali v tedensko naraščajočih odmerkih od 4 - 20 mg štirikrat na dan 6 tednov.
Your ability to drive or use a machine may be affected if your blood sugar is low or high.
Vaša sposobnost za vožnjo ali upravljanje s stroji se lahko spremeni, če je vaš sladkor v krvi previsok ali prenizek.
If you forget to take Repaglinide Teva If you miss a dose, take the next dose as usual - do not double the dose.
Če ste pozabili vzeti zdravilo Repaglinid Teva Če izpustite odmerek, vzemite naslednji odmerek kot ponavadi - ne podvajajte odmerka.
Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Na podlagi izkušenj z repaglinidom in drugimi antidiabetiki so bili ugotovljeni naslednji neželeni učinki: opredelitev pogostnosti je: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Your body's response to Repaglinide Teva may change if you take other medicines, especially these:
Vaš odziv na zdravilo Repaglinid Teva se lahko spremeni, če jemljete še druga zdravila, še posebno:
• Diabetes mellitus type 1, C-peptide negative.
• Sladkorna bolezen tipa 1 (negativni C-peptid).
If any change of your treatment is necessary contact your doctor first.
Če je potrebna kakršna koli sprememba zdravljenja, se najprej posvetujte z zdravnikom.
Rare (may affect up to 1 in 1,000 patients) • Acute coronary syndrome (but it may not be due to the medicine).
Redki (pojavijo se lahko pri največ 1 od 100 bolnikov) • akutni koronarni sindrom (ki pa lahko ni posledica zdravila)
Repaglinide Teva may not be suitable for you.
Zdravilo Repaglinid Teva za vas morda ni primerno.
You should not take Repaglinide Teva if you are pregnant or you are planning to become pregnant.
Ne jemljite zdravila Repaglinid Teva, če ste noseči ali nameravate zanositi.
• Hypersensitivity to repaglinide or to any of the excipients listed in section 6.1.
• Preobčutljivost za repaglinid ali katerokoli pomožno snov, navedeno v poglavju 6.1.
Please ask your doctor whether you can drive a car if you:
Posvetujte se z zdravnikom, ali naj sploh vozite ali upravljate s stroji, če:
In this case, the dosage of metformin should be maintained and repaglinide administered concomitantly.
V tem primeru je treba odmerjanje metformina ohraniti in sočasno uporabiti repaglinid.
This may be due to progression of the severity of the diabetes or to diminished responsiveness to the medicinal product.
To je morda posledica napredovanja sladkorne bolezni ali zmanjšane odzivnosti na zdravilo.
When repaglinide is used together with other medicinal products that are mainly secreted by the bile, like repaglinide, any potential interaction should be considered.
Če se repaglinid uporablja z drugimi zdravili, ki se izločajo predvsem v žolču, tako kot repaglinid, je treba upoštevati morebitne interakcije.
Repaglinide pharmacokinetics are characterised by a mean absolute bioavailability of 63% (CV 11%).
Za farmakokinetiko repaglinida so značilni 63% povprečna absolutna biološka uporabnost (CV 11%).
Consequently metabolism, and by that clearance of repaglinide, may be altered by substances which influence these cytochrome P-450 enzymes via inhibition or induction.
Zato se presnova in s tem tudi očistek repaglinida lahko spremenita zaradi učinkovin, ki vplivajo na te citokrom P-450 encime bodisi z inhibicijo ali indukcijo.
• If you are allergic to repaglinide or any of the other ingredients in this medicine (listed in section 6).
• če ste alergični na repaglinid ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1).
Na podlagi podatkov in vitro kaže, da je repaglinid substrat aktivnega prevzema v jetrih (transportna beljakovina organskih anionov OATP1B1).
This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia.
To je posebno pomembno pri bolnikih z zmanjšanim ali odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
Substances that inhibit OATP1B1 may likewise have the potential to increase plasma concentrations of repaglinide, as has been shown for ciclosporin (see below).
Učinkovine, ki zavirajo OATP1B1, lahko morda koncentracijo repaglinida v plazmi zvišajo podobno, kot je ugotovljeno za ciklosporin (glejte spodaj).
As hypoglycaemia in this study was avoided through increased calorie intake, a relative overdose may result in an exaggerated glucose-lowering effect with development of hypoglycaemic symptoms (dizziness, sweating, tremor, headache etc.).
Ker so se hipoglikemiji v tej študiji izognili z večjim kaloričnim vnosom, lahko relativno preveliko odmerjanje povzroči čezmerno znižanje glukoze in pojav simptomov hipoglikemije (omotica, znojenje, tremor, glavobol itn.).
Do not take more Repaglinide Teva than your doctor has recommended.
Ne vzemite več zdravila Repaglinid Teva, kot vam je svetoval zdravnik.
Do not use this medicine after the expiry date which is stated on the carton and blister foil after EXP.
Tega zdravila Repaglinid Teva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake »EXP«.
Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i.e. primary failure) and to detect loss of adequate blood glucose-lowering response after an initial period of effectiveness (i.e. secondary failure).
Redno spremljanje je potrebno, da bi odkrili nezadostno znižanje glukoze v krvi ob priporočenem največjem odmerku (tj. primarno odpoved), ali nezadostno znižanje glukoze po uvodnem obdobju učinkovitosti (tj. sekundarno odpoved).
They include: increased urination; feeling thirsty; dry skin and dry mouth.
povečano uriniranje, občutek žeje, suha koža in suha usta.
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo varnostne ukrepe, da bi preprečili hipoglikemijo med upravljanjem vozila.
This phenomenon is known as secondary failure, to distinguish it from primary failure, where the medicinal product is ineffective in an individual patient when first given.
Pojav je poznan kot sekundarna odpoved, za razliko od primarne odpovedi, pri kateri je zdravilo neučinkovito, že ko ga posameznik dobi prvič.
Use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials.
Uporaba repaglinida v primerih sekundarne odpovedi sekretagogov insulina ni bila raziskana v kliničnih preskušanjih.
There are no studies of repaglinide in pregnant women.
Študij o uporabi repaglinida pri nosečnicah ni.
Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
Zdravljenje je treba začeti kot dodatek k dieti in telesni dejavnosti za znižanje glukoze v krvi ob obrokih.
• The normal starting dose is 0.5 mg before each main meal.
• Običajni začetni odmerek je 0,5 mg tik pred vsakim glavnim obrokom.
Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka (pankreas) ne tvori dovolj insulina, da bi uravnal koncentracijo sladkorja v krvi ali se vaše telo ne odziva normalno na insulin, ki ga sam proizvaja.
More severe hypoglycaemia with seizure, loss of consciousness or coma should be treated with intravenous glucose.
Hujšo hipoglikemijo s konvulzijami, izgubo zavesti ali komo je treba zdraviti z intravensko aplikacijo glukoze.
Teva Pharmaceuticals Works Private Limited Company H-2100 Gödöllö,
TEVA Pharmaceutical Works Private Limited Company H-2100 Gödöllö
Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they must turn you on your side and get medical help straight away.
Ljudem povejte, da vas morajo v primeru, če se onesvestite (izgubite zavest), položiti na bok in nemudoma poiskati zdravniško pomoč.
Combination with metformin Combination treatment with metformin is associated with an increased risk of hypoglycaemia.
Kombinirano zdravljenje z metforminom spremlja večja nevarnost hipoglikemije.
• Oral contraceptives (birth control pills).
• peroralne kontraceptive (tablete za nadzorovanje rojstev),